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diopathic pulmonary fibrosis (IPF) is the most prevalent of
the idiopathic interstitial pneumonias and its incidence
seems to be increasing [1–4]. IPF is generally considered to
be unresponsive to ‘‘standard’’ therapies and carries a poor
prognosis with most patients dying within at least 5 years
following diagnosis [5–7]. An accurate diagnosis of IPF is
essential for the optimal management of patients with IPF. The
original IPF management guidelines, published in 2000 [8],
have been superseded recently by the evidence-based interna-
tional recommendations jointly sponsored by the European
Respiratory Society (ERS), the American Thoracic Association
(ATS), the Japanese Respiratory Society (JRS) and the Latin
American Thoracic Association (ALAT) [9]. Nonetheless,
despite this and other major accomplishments over the last
decade, the diagnosis and the management of IPF remain a
major medical challenge. Diagnostic uncertainties remain due,
at least in part, to variability in the natural history of the
disease and co-existing complicating comorbidities, interpreta-
tion and widespread application of the guideline recommen-
dations, and analysis of histological and radiographic assays,
as well as a paucity of accurate indicators of disease
progression and response to treatment.
Since a cure for IPF is not currently available, the treatment goal
is to stabilise or reduce the rate of disease progression. There
have been significant and encouraging increases in the number,
size and quality of randomised clinical trials in IPF over the past
decade (fig. 1) [10–23], and novel anti-fibrotic agents with the
potential to realise this treatment goal are now starting to
emerge. For example, although the 2011 guidelines committee
did not recommend any single pharmacological agent, pirfeni-
done has been approved for clinical use in Europe.
The identification of more accurate and objective predictors of
clinical status, prognosis and survival estimates in IPF is also
critical for clinical management and individual treatment
decision making [24]. There is also an ongoing debate on the
choice of primary end-point for use in clinical trials of
treatments for IPF. Improvements in molecular techniques have
expanded our understanding of IPF and have led to the
identification of new molecular pathways, thus shaping the
potential for a more targeted therapeutic approach [25, 26].
While genetic studies have provided some insights into the
pathogenesis of IPF, more functional studies that confirm their
significance and studies investigating other mutations, associa-
tions and gene–environment relationships are required [27–30].
This issue of the European Respiratory Review includes a series
of state-of-the-art articles based on presentations by prominent
IPF experts at the recent 2012 ERS Annual Congress in Vienna,
Austria, and the 17th International Colloquium on Lung and
Airways Fibrosis (ICLAF) held in Modena, Italy. The articles
review the substantial progress that has been made in the
pathogenesis, diagnosis, management and treatment of IPF,
but also anticipate the future advances in the understanding
and clinical management of IPF. In the first article, WELLS [31]
provides a critical review and the latest insights into managing
diagnostic procedures in IPF and identifies limitations that
should be addressed in future consensus statements. BEHR [32]
then provides an updated evaluation of clinical study and
evidence-based data of novel treatment strategies in IPF,
including the latest results from the pirfenidone CAPACITY
(Clinical Studies Assessing Pirfenidone in Idiopathic Pulmo-
nary Fibrosis: Research of Efficacy and Safety Outcomes)
clinical trials and the subsequent open-label extension study,
RECAP (Open-label roll-over study from CAPACITY). MAHER
[33] goes on to identify the most recent potential biomarkers
and disease fingerprint of IPF and describes the ongoing
PROFILEing (Prospective Observation of Fibrosis in the Lung
Clinical Endpoints) Study, an innovative UK-based multi-
centre prospective cohort study that aims to characterise
composite biological and clinical trial end-points. Finally,
COTTIN [34] describes the impact of a new syndrome, in which
pulmonary fibrosis co-exists with pulmonary emphysema.
Combined pulmonary fibrosis and emphysema (CPFE) is a
strong determinant of secondary pulmonary hypertension and
further studies are needed to ascertain the aetiology, morbid-
ity, mortality and management of CPFE, with or without
pulmonary hypertension, and to evaluate novel therapeutic
options.
The expert contributions in this series of articles indicate that there
is room for cautious optimism in this challenging era of respiratory
medicine, and that we may be entering an era in which preven-
tion of IPF progression may become a reasonable therapeutic
goal. Recently updated guidelines have provided important
recommendations for the diagnosis and pharmacological and
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non-pharmacological management of patients with IPF. The
ability of physicians to achieve a confident diagnosis has greatly
improved, and the proliferation of clinical trials has started to
build an evidence base upon which rational treatment decisions
can be built.
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FIGURE 1. The number of patients enrolled in clinical studies of idiopathic pulmonary fibrosis (IPF) has increased substantially in the past decade compared to the
previous decade [10–23].
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